Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$334.00K$334.00K— vs Q2 2020 Net Income-$3.30M-$3.30MN/M vs Q2 2020 EPS Diluted-$0.05-$0.05N/M vs Q2 2020 Operating Income-$3,293,700N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-986.1%
Net margin-987.4%
ended Sep 30, 2020 · filed Nov 12, 2020 · 43 d after period end